Compare · DFTX vs UPXI
DFTX vs UPXI
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Upexi Inc. (UPXI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and UPXI operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.60B, about 49.3x UPXI ($93.5M).
- DFTX has been more active in the news (11 items in the past 4 weeks vs 5 for UPXI).
- DFTX has more recent analyst coverage (8 ratings vs 2 for UPXI).
- Company
- Definium Therapeutics Inc.
- Upexi Inc.
- Price
- -
- -
- Market cap
- $4.60B
- $93.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 11
- 5
- Recent ratings
- 8
- 2
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.
Latest UPXI
- SEC Form 8-K filed by Upexi Inc.
- SEC Form DEF 14A filed by Upexi Inc.
- SEC Form 8-K filed by Upexi Inc.
- Upexi to Participate in Upcoming October Investor Conferences
- SEC Form PRE 14A filed by Upexi Inc.
- Upexi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-K filed by Upexi Inc.
- Upexi Reports Financial Results for Fiscal Year Ended June 30, 2026
- Upexi Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Upexi to Host Fiscal Year 2026 Earnings Call on Thursday, September 17th at 5:30 P.M. ET